HRP20090550T1 - UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA - Google Patents

UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA Download PDF

Info

Publication number
HRP20090550T1
HRP20090550T1 HR20090550T HRP20090550T HRP20090550T1 HR P20090550 T1 HRP20090550 T1 HR P20090550T1 HR 20090550 T HR20090550 T HR 20090550T HR P20090550 T HRP20090550 T HR P20090550T HR P20090550 T1 HRP20090550 T1 HR P20090550T1
Authority
HR
Croatia
Prior art keywords
use according
epa
dha
drug
ethyl ester
Prior art date
Application number
HR20090550T
Other languages
English (en)
Croatian (hr)
Inventor
Bruzzese Tiberio
Original Assignee
Bruzzese Tiberio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bruzzese Tiberio filed Critical Bruzzese Tiberio
Publication of HRP20090550T1 publication Critical patent/HRP20090550T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20090550T 2004-01-21 2005-01-20 UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA HRP20090550T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

Publications (1)

Publication Number Publication Date
HRP20090550T1 true HRP20090550T1 (hr) 2010-01-31

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090550T HRP20090550T1 (hr) 2004-01-21 2005-01-20 UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA

Country Status (12)

Country Link
US (1) US8829048B2 (enExample)
EP (1) EP1706106B9 (enExample)
JP (1) JP5087280B2 (enExample)
DE (1) DE602005015415D1 (enExample)
DK (1) DK1706106T3 (enExample)
ES (1) ES2329809T3 (enExample)
HR (1) HRP20090550T1 (enExample)
IT (1) ITMI20040069A1 (enExample)
PL (1) PL1706106T3 (enExample)
PT (1) PT1706106E (enExample)
RS (1) RS51195B (enExample)
WO (1) WO2005070411A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US7652068B2 (en) * 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
EP3263101A1 (en) 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
PT2144618E (pt) 2007-03-28 2013-07-08 Aker Biomarine Asa Composições bioeficazes de óleo de krill
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20110166229A1 (en) * 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
KR102310765B1 (ko) 2015-02-11 2021-10-12 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
WO2022050355A1 (ja) * 2020-09-04 2022-03-10 国立大学法人千葉大学 ドコサヘキサエン酸、ドコサヘキサエノイル基含有ホスファチジン酸、又はその誘導体によるセロトニントランスポーター関連精神疾患の予防・治療剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) * 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US6331568B1 (en) * 1996-10-11 2001-12-18 Scotia Holdings Plc. Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
IT1320180B1 (it) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
DE602005015415D1 (de) 2009-08-27
EP1706106B9 (en) 2009-09-16
PL1706106T3 (pl) 2009-12-31
JP5087280B2 (ja) 2012-12-05
RS51195B (sr) 2010-10-31
US20070161705A1 (en) 2007-07-12
PT1706106E (pt) 2009-09-04
DK1706106T3 (da) 2009-10-12
EP1706106A1 (en) 2006-10-04
EP1706106B1 (en) 2009-07-15
US8829048B2 (en) 2014-09-09
JP2007518764A (ja) 2007-07-12
WO2005070411A1 (en) 2005-08-04
ES2329809T3 (es) 2009-12-01
ITMI20040069A1 (it) 2004-04-21

Similar Documents

Publication Publication Date Title
HRP20090550T1 (hr) UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA
Darwesh et al. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?
JP2007518764A5 (enExample)
FR2860976B1 (fr) Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
ES2613606T3 (es) Uso de derivados de ácidos grasos polinsaturados como medicamentos
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
JP2015143248A5 (enExample)
EP1534261A4 (en) EPA AND DHA ENHANCED OMEGA-3 SUPPLEMENT FOR THE TREATMENT OF DRY EYE, MEIBOMIANITIS AND XEROSTOMY
RU2001121185A (ru) Этил-ЭПК с высокой степенью чистоты и другие производные ЭПК для психиатрических и неврологических расстройств
JP2014512351A5 (enExample)
RU2002133098A (ru) Терапевтические комбинации жирных кислот
UA89207C2 (ru) Применение длинноцепочечных полиненасыщенных жирных кислот для получения жидкой питательной смеси для кормления детей
JP7335475B2 (ja) 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
HRP20200394T1 (hr) Smjesa masnih kiselina (gmk, grupa masnih kiselina) za primjenu u liječenju inflamatornih patologija
JP2006528233A5 (enExample)
FR2878747B1 (fr) Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
HRP20160939T1 (hr) Pripravci za liječenje neuroloških poremećaja
WO2012049227A3 (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
RU2019110681A (ru) Фармацевтическая композиция
JP2017523230A5 (enExample)
JP2016501248A5 (enExample)
JP2008540484A5 (enExample)
WO2005053669A8 (fr) Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
Nadjar et al. Antiinflammatory properties of dietary n-3 polyunsaturated fatty acids protect against cognitive decline in aging and neurodegenerative diseases